Unknown

Dataset Information

0

Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?


ABSTRACT: Some patients administered cholesterol-lowering therapies may experience an increase in the proportion of small LDL particles, which may be misinterpreted as a worsening of atherosclerotic coronary heart disease risk. This study assessed the lipid effects of adding ezetimibe to atorvastatin or doubling the atorvastatin dose on low-density lipoprotein cholesterol (LDL-C) levels (and the cholesterol content of LDL subclasses), LDL particle number (approximated by apolipoprotein B), and LDL particle size. This was a multicenter, double-blind, randomized, parallel-group study of hypercholesterolemic, high atherosclerotic coronary heart disease risk patients. After stabilization of atorvastatin 40 mg, 579 patients with LDL-C >70 mg/dL were randomized to 6 weeks of ezetimibe + atorvastatin 40 mg or atorvastatin 80 mg. Efficacy parameters included changes from baseline in LDL-C, apolipoprotein B, non-high-density lipoprotein cholesterol (non-HDL-C), and lipoprotein subclasses (Vertical Auto Profile II) and pattern for the overall population, as well as patient subgroups with baseline triglyceride levels <150 mg/dL or ?150 mg/dL.Both treatments significantly reduced LDL-C (and the cholesterol content of most LDL subfractions [LDL1-4]) apolipoprotein B, non-HDL-C levels, but did not reduce the proportion of smaller, more dense LDL particles; in fact, the proportion of Pattern B was numerically increased. Results were generally similar in patients with triglyceride levels <150 or ?150 mg/dL.When assessing the effects of escalating cholesterol-lowering therapy, effects upon Pattern B alone to assess coronary heart disease risk may be misleading when interpreted without considerations of other lipid effects, such as reductions in LDL-C, atherogenic lipoprotein particle concentration, and non-HDL-C levels.(Registered at clinicaltrials.gov: Clinical trial # NCT00276484).

SUBMITTER: Bays H 

PROVIDER: S-EPMC3012666 | biostudies-literature | 2010 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?

Bays Harold H   Conard Scott S   Leiter Lawrence A LA   Bird Steven S   Jensen Erin E   Hanson Mary E ME   Shah Arvind A   Tershakovec Andrew M AM  

Lipids in health and disease 20101130


<h4>Background</h4>Some patients administered cholesterol-lowering therapies may experience an increase in the proportion of small LDL particles, which may be misinterpreted as a worsening of atherosclerotic coronary heart disease risk. This study assessed the lipid effects of adding ezetimibe to atorvastatin or doubling the atorvastatin dose on low-density lipoprotein cholesterol (LDL-C) levels (and the cholesterol content of LDL subclasses), LDL particle number (approximated by apolipoprotein  ...[more]

Similar Datasets

| S-EPMC2783869 | biostudies-literature
| S-EPMC8830607 | biostudies-literature
| S-EPMC4052434 | biostudies-literature
| S-EPMC5558541 | biostudies-literature
| S-EPMC4617360 | biostudies-literature
| S-EPMC8635697 | biostudies-literature
| S-EPMC10143414 | biostudies-literature
| S-EPMC10359670 | biostudies-literature
| S-EPMC7157586 | biostudies-literature
| S-EPMC5698121 | biostudies-literature